Aldesleukin Completed Phase 1 Trials for Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific / Malignant Lymphomas Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00003993Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma
NCT00005604Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors
NCT00019357Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy
NCT00182650Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
NCT00058045Interleukin-2 and Stem Cell Factor in Treating Patients With AIDS or AIDS-Related Cancer
NCT00020462Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma
NCT00002687Interleukin-2 in Treating Patients With Mycosis Fungoides